Primary composite outcome

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

There was no difference in the primary outcome between verapamil SR-based and atenolol-based treatment strategies for any age group, including the very old.

Effect: null; No difference (Figure 4)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)

The relationship between on-treatment systolic blood pressure and primary outcome in very old hypertensive CAD patients follows a J-shaped curve, with the hazard ratio nadir at 140 mm Hg -- higher tha

Effect: mixed; HR nadir at SBP 140 mm Hg for very old (vs 110 mm Hg for aged <60 and 60-<70, and 135 mm Hg for aged 70-<80)